Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma appoints cancer immunotherapy experts

Ronald Levy, Zelig Eshhar and Inder Verma will offer expert advice to US biotech

Ronald Levy, Kite Pharma Kite Pharma has added three experts in cancer immunotherapy to its scientific advisory board.

Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder Verma is chair of exemplary science and American Cancer Society professor of molecular biology at The Salk Institute.

Their expertise will help the US biotech develop medicines that activate the body's T cells to fight tumours.

Cancer immunotherapies are becoming a popular method of treatment for investigation in oncology, with big deals involving the likes of Bayer, Merck Serono, GSK and Roche.

"Kite is fortunate to attract these world-leading immunotherapy and cancer researchers to our advisory board," said Dr Aya Jakobovits, president and CEO of Kite.

Article by
Thomas Meek

12th August 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...